title: [Sub-classification of diffuse large B-cell lymphoma by semi-quantification of the CD5 expression with flow cytometric analysis].
abstract: CD5+ diffuse large B-cell lymphoma(CD5+DLBCL) is known to have different characteristics than CD5-DLBCL and mantle cell lymphoma(MCL). 9 patients with CD5+DLBCL were reviewed, and the results were compared with those of 8 CD5-DLBCL and 3 cyclin D1+MCL patients. CD5+DLBCL was more closely related to many aggressive clinical features or parameters than CD5-DLBCL: 67% of the patients were older than 60 years, 67% with performance status > or = 2, 89% with serum lactate dehydrogenase level higher than normal, 78% with stage III/IV disease at diagnosis, and 78% with more than one extranodal lesion. The overall International Prognostic Index score for the patients with CD5+DLBCL was thus significantly higher than that for those with CD5-DLBCL. Immunophenotypically, CD5+DLBCL was characterized by CD5+CD10-CD19+CD20+CD21-CD23-cyclin D1-phenotype and the predominant expression of surface IgM. Of particular interest is that the survival rate of CD5+DLBCL patients was significantly inferior to that of patients with CD5-DLBCL. To further characterize CD5+DLBCL, we semi-quantified the CD5 expression in DLBCL cells. Our findings suggest that CD5+DLBCL may constitute a unique subgroup of DLBCL and, moreover, CD5+DLBCL may consist of several subgroups.
authors.affiliation: Department of Medical Technology, Kagawa Prefectural College of Health Sciences, Kida-gun, Kagawapref, 761-0123.
authors.forename: Noriko
authors.initials: N
authors.lastname: Manabe
authors.forename: Genji
authors.initials: G
authors.lastname: Yamaoka
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ohnishi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Arai
authors.forename: Hiromi
authors.initials: H
authors.lastname: Nakaishi
authors.forename: Tatushi
authors.initials: T
authors.lastname: Kajikawa
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Kubota
authors.forename: Terukazu
authors.initials: T
authors.lastname: Tanaka
authors.forename: Akira
authors.initials: A
authors.lastname: Kitanaka
authors.forename: Masato
authors.initials: M
authors.lastname: Waki
authors.forename: Kimihiro
authors.initials: K
authors.lastname: Kawakami
authors.forename: Masami
authors.initials: M
authors.lastname: Nagai
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ishida
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Taminato
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018956:CD5 Antigens / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016393:Lymphoma, B-Cell / Q000145:classification* / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate
chemical_list: D018956:CD5 Antigens